EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A chimeric mRNA vaccine of S-RBD with HA conferring broad protection against influenza and COVID-19 variants

Tianjiao Hao, Yulei Li, Peipei Liu, Xi Wang, Ke Xu, Wenwen Lei, Ying Li, Rong Zhang, Xiaoyan Li, Xin Zhao, Kun Xu, Xuancheng Lu und 5 weitere

PLOS Pathogens · 2024

DOI: 10.1371/journal.ppat.1012508 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Pathogens, 2024. Verfasst von Tianjiao Hao und 16 weiteren Autor:innen. Beteiligte Einrichtung: CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, People's Republic of Chi…. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19, mRNA Vaccines, Spike Glycoprotein, Coronavirus. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Projects of the Ministry of Science and Technology of China, National Natural Science Foundation of China, CAS Project for Young Scientists in Basic Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Influenza and coronavirus disease 2019 (COVID-19) represent two respiratory diseases that have significantly impacted global health, resulting in substantial disease burden and mortality. An optimal solution would be a combined vaccine capable of addressing both diseases, thereby obviating the need for multiple vaccinations. Previously, we conceived a chimeric protein subunit vaccine targeting both influenza virus and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), utilizing the receptor binding domain of spike protein (S-RBD) and the stalk region of hemagglutinin protein (HA-stalk) components. By integrating the S-RBD from the SARS-CoV-2 Delta variant with the headless hemagglutinin (HA) from H1N1 influenza virus, we constructed stable trimeric structures that remain accessible to neutralizing antibodies. This vaccine has demonstrated its potential by conferring protection against a spectrum of strains in mouse models. In this study, we designed an mRNA vaccine candidate encoding the chimeric antigen. The resultant humoral and cellular immune responses were meticulously evaluated in mouse models. Furthermore, the protective efficacy of the vaccine was rigorously examined through challenges with either homologous or heterologous influenza viruses or SARS-CoV-2 strains. Our findings reveal that the mRNA vaccine exhibited robust immunogenicity, engendering high and sustained levels of neutralizing antibodies accompanied by robust and persistent cellular immunity. Notably, this vaccine effectively afforded complete protection to mice against H1N1 or heterosubtypic H5N8 subtypes, as well as the SARS-CoV-2 Delta and Omicron BA.2 variants. Additionally, our mRNA vaccine design can be easily adapted from Delta RBD to Omicron RBD antigens, providing protection against emerging variants. The development of two-in-one vaccine targeting both influenza and COVID-19, incorporating the mRNA platform, may provide a versatile approach to combating future pandemics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2COVID-19mRNA VaccinesSpike Glycoprotein, CoronavirusHemagglutinin Glycoproteins, Influenza VirusCOVID-19 VaccinesAnimalsMiceHumansInfluenza VaccinesAntibodies, ViralMice, Inbred BALB CFemaleInfluenza A Virus, H1N1 SubtypeOrthomyxoviridae InfectionsVaccines, SyntheticInfluenza, HumanAntibodies, Neutralizing

Substanzen

mRNA VaccinesSpike Glycoprotein, CoronavirusHemagglutinin Glycoproteins, Influenza VirusCOVID-19 VaccinesInfluenza VaccinesAntibodies, ViralVaccines, SyntheticAntibodies, Neutralizingspike protein, SARS-CoV-2

Autor:innen und Institutionen

  • CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, People's Republic of China.
  • University of Chinese Academy of Sciences, Beijing, People's Republic of China.
  • Clinicopathological Diagnosis & Research Center, the Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, People's Republic of China.
  • Key Laboratory of Tumor Molecular Pathology of Guangxi Higher Education Institutes, Baise, People's Republic of China.
  • NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People's Republic of China.
  • State Key Laboratory for Conservation and Utilization of Subtropical Agro-Bioresources, Guangxi University, Nanning, People's Republic of China.

ORCID-Profile: Hao Song, George F Gao

Förderung

  • National Key Research and Development Projects of the Ministry of Science and Technology of China
  • National Natural Science Foundation of China
  • CAS Project for Young Scientists in Basic Research
  • Youth Innovation Promotion Association CAS
  • Strategic Priority Research Program of CAS
  • Youth Innovation Promotion Association of the Chinese Academy of Sciences
  • Baise Science and Technology Plan Project

Zitieren

APA

Hao, T., Li, Y., Liu, P., Wang, X., Xu, K., Lei, W., Li, Y., Zhang, R., Li, X., Zhao, X., Xu, K., Lu, X., Bi, Y., Song, H., Wu, G., Zhu, B., & Gao, G. F. (2024). A chimeric mRNA vaccine of S-RBD with HA conferring broad protection against influenza and COVID-19 variants. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1012508

Vancouver

Hao T, Li Y, Liu P, Wang X, Xu K, Lei W, et al. A chimeric mRNA vaccine of S-RBD with HA conferring broad protection against influenza and COVID-19 variants. PLOS Pathogens. 2024. doi:10.1371/journal.ppat.1012508

BibTeX
@article{Hao2024,
  author = {Hao, Tianjiao and Li, Yulei and Liu, Peipei and Wang, Xi and Xu, Ke and Lei, Wenwen and Li, Ying and Zhang, Rong and Li, Xiaoyan and Zhao, Xin and Xu, Kun and Lu, Xuancheng and Bi, Yuhai and Song, Hao and Wu, Guizhen and Zhu, Baoli and Gao, George F},
  title = {A chimeric mRNA vaccine of S-RBD with HA conferring broad protection against influenza and COVID-19 variants},
  journal = {PLOS Pathogens},
  year = {2024},
  doi = {10.1371/journal.ppat.1012508}
}
Kostenlos starten →